Sydney, Nov 23, 2005 AEST (ABN Newswire) - Clinical Cell Culture Ltd (ASX: CCE) is pleased to announce the appointment of Helicon Group (Helicon), through their Chinese partner Cobra Bio Health Services International (Cobra), as the distributor of ReCell(R) in China.
C3 Managing Director Troels Jordansen said the appointment of a Chinese distributor represented an important step in the continued global commercialisation of ReCell(R). "We are delighted to have secured agreement with Helicon and Cobra for distribution of ReCell(R) in a key and expanding market," said Mr Jordansen.
"First year sales forecasts of 1,400 ReCell(R) devices indicate that China will become a significant market for ReCell(R) products and by partnering with companies who have a specific focus on China we now have unparalleled access to this expanding market. ReCell(R) is expected to be launched in China in mid 2006 following completion of the regulatory approval process."
ReCell(R) is already available in 26 countries around the world and is promoted by in excess of 200 sales agents through C3's distributor network. Regulatory approval to sell ReCell(R) is being sought in a number of additional key markets, including China.
Helicon CEO Mr Peter Abrahamson said China represented an exciting opportunity for the ReCell(R) technology in both the cosmetic and burns markets. "China's rapidly emerging middle class is demanding high end leading edge technologies and elective plastic and cosmetic surgery has experienced rapid growth in China in recent years. The market is estimated to have a value in the order of US$2.4billion and the industry employs over 6 million people," said Mr Abrahamson, previously Vice President of Allergan Inc's East Asia business. "Helicon is excited and pleased to have been appointed as the China partner to commercialise ReCell(R). ReCell(R) represents an innovative technology with significant short and medium term revenue potential in China."
Cobra President Mr Michael Chrisp said Cobra is pleased and excited to partner with C3 and Helicon for the registration and commercialisation of ReCell(R) in the cosmetic, dermatological, and burns markets in China. "The entire China based Cobra team is eagerly looking forward to the earliest possible China State Food and Drug Administration approval for ReCell R and to being able to realise the considerable product potential," said Mr Chrisp.
Contact
Andrew Cannon or Troels Jordansen
Clinical Cell Culture
Tel: +44 (0)1223 341 150
Email: investor@clinicalcellculture.com
| ||
|
